Therapy in Type 2 Diabetes: Insulin Glargine vs. NPH Insulin Both in Combination with Glimepiride

Eliaschewitz, Freddy Goldberg; Calvo, C.; Valbuena, Humberto; Ruiz, Maximino; Aschner, Pablo; Villena, Jaime; Ramírez, Luis Alberto; Jimenez, J.

doi:10.1016/j.arcmed.2005.10.015

Cited by 107 publications

(123 citation statements)

References 15 publications

Supporting

Mentioning

115

Contrasting

Unclassified

Order By: Relevance

“…In addition, changes in body weight were neither statistically nor clinically significant. This result is in concordance with the findings in randomized clinical trials [2,5,14,23]. The neutral effect of glargine on body weight in this study may be due to increased self-care behaviors, improvement in lifestyle and nutritional status of the participants [24] suggesting that insulin glargine may be more beneficial in treating obese patients with T2DM [25].…”

Section: Discussionsupporting

confidence: 82%

“…Newer insulin therapies such as different types of insulin analogues trying to simulate the physiologic basal-prandial insulin have changed clinical diabetes care [14,15]. Insulin glargine (LANTUS; Sanofi-Aventis, Paris, France) is a basal insulin analogue with no pronounced peak, consistent activity profile [16], and lower risk of nocturnal hypoglycemia compared with neutral protamine Hagedorn (NPH) insulin in patients with T2DM [2]. It has been shown that insulin glargine can be used to treat to glycemic targets <7.0% in insulin naïve patients [17,18].…”

Section: Introductionmentioning

confidence: 99%

“…In patients with type 2 diabetes mellitus (T2DM), prolonged hyperglycemia is associated with longterm microvascular and macrovascular complications [2][3][4]. It has been demonstrated that maintaining tight glycemic control decreases the risks of long-term complications, as well as mortality and morbidity [5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Practical Focus on American Diabetes Association/European Association for the Study of Diabetes Consensus Algorithm in Patients with Type 2 Diabetes Mellitus: Timely Insulin Initiation and Titration (Iran-AFECT)

et al. 2017

View full text Add to dashboard Cite

Background:The aim of this study was to evaluate the safety and effectiveness of insulin glargine in a large population from a variety of clinical care in Iranian people with type 2 diabetes mellitus (T2DM) and to measure the percentage of patients achieving glycosylated hemoglobin (HbA1c) <7% by the end of 24 weeks of treatment in routine clinical practice. Methods: This study was a 24 week, observational study of patients with T2DM, for whom the physician had decided to initiate or to switch to insulin glargine. The safety and efficacy of glargine were assessed at baseline and at week 24. Results: Seven hundred and twenty-five people with T2DM (63% female) including both insulin naïve and prior insulin users were recruited in this study. The mean age of the participants was 54.2±11.2 years, and the mean HbA1c level was 8.88%±0.93% at baseline. By the end of the study, 27% of the entire participants reached to HbA1c target of less than 7% and 52% had HbA1c ≤7.5%. No serious adverse event was reported in this study. Furthermore, overall hypoglycemia did not increase in prior insulin users and the entire cohort. In addition, body weight did not change in participants while lipid profile improved significantly. Conclusion: Treatment with insulin glargine could improve glycemic control without increasing the risk of hypoglycemic events in people with T2DM. In addition, a significant clinical improvement was observed in lipid profile.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Practical Focus on American Diabetes Association/European Association for the Study of Diabetes Consensus Algorithm in Patients with Type 2 Diabetes Mellitus: Timely Insulin Initiation and Titration (Iran-AFECT)

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Numerous studies have investigated the benefits of adding long-acting basal insulin analogs, specifically insulin glargine, to oral hypoglycemic treatment in comparison to NPH insulin in patients with T2DM and poor glycemic control [11,[15][16][17]. Although, in general, both regimens have been shown to be effective in controlling blood glucose levels, treatments based on administration of insulin glargine appear to achieve target HbA1c levels with a lower incidence of hypoglycemic episodes and to have greater effectiveness in metabolic control in these patients.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of therapy with basal insulin analogs to improve glycemic control in type 2 diabetes mellitus patients poorly controlled with oral antidiabetic drugs in combination or not with NPH insulin

Soto-González¹,

Guerrero²

2013

J Diab Res Clin Met

View full text Add to dashboard Cite

“…These studies have ranged in duration from 4 weeks to 5 years. [11][12][13][14][15][16][17][18][19][20] Baseline characteristics of the individuals studied have ranged from 27 to 35 kg/m 2 for body mass index, 55 to 62 years for age, and 8.3% to 9.7% for A1c. In most studies insulin was given once daily at bedtime, although one S-34 HEDRINGTON ET AL.…”

Section: Pharmacodynamics and Pharmacokineticsmentioning

confidence: 99%

Basal Insulin Treatment in Type 2 Diabetes

Hedrington

Pulliam

2011

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

Insulin glargine is the first 24-h recombinant DNA insulin analog introduced to the market. Substitution of glycine for asparagine and addition of two arginine residues raise the isoelectric point of insulin glargine and result in microprecipitates, delaying absorption from subcutaneous tissue. This delayed absorption result in fairly flat 24-h insulin concentration profiles with no discernible peak. Large, multicenter, randomized, controlled trials in patients with type 2 diabetes show that although NPH insulin and insulin glargine are equally effective in lowering glycosylated hemoglobin (A1c) and fasting blood glucose, there is a clear advantage of insulin glargine over NPH insulin in reducing nocturnal and overall hypoglycemia. Lower risk of hypoglycemia with glargine was also consistently demonstrated by trials comparing insulin glargine and premixed analog insulins. These studies also showed greater reduction in A1c with twice-daily premixed insulins compared with glargine, when insulin glargine was administered without mealtime insulin coverage. Insulin glargine was also compared with another insulin analog, insulin detemir. Trials showed that both insulin analogs are equally effective in lowering A1c and have comparable risk of hypoglycemia. Trials comparing insulin glargine with glucagon-like peptide-1 agonists showed comparable significant reductions in A1c with both regimens. Insulin glargine is well tolerated, has low immunogenicity, reduced risks for acute myocardial infarction, and a lower risk of hypoglycemia compared with NPH insulin in individuals with type 2 diabetes.

show abstract

Therapy in Type 2 Diabetes: Insulin Glargine vs. NPH Insulin Both in Combination with Glimepiride

Cited by 107 publications

References 15 publications

Practical Focus on American Diabetes Association/European Association for the Study of Diabetes Consensus Algorithm in Patients with Type 2 Diabetes Mellitus: Timely Insulin Initiation and Titration (Iran-AFECT)

Practical Focus on American Diabetes Association/European Association for the Study of Diabetes Consensus Algorithm in Patients with Type 2 Diabetes Mellitus: Timely Insulin Initiation and Titration (Iran-AFECT)

Effectiveness of therapy with basal insulin analogs to improve glycemic control in type 2 diabetes mellitus patients poorly controlled with oral antidiabetic drugs in combination or not with NPH insulin

Basal Insulin Treatment in Type 2 Diabetes

Contact Info

Product

Resources

About